Kalvista Pharmaceuticals Stock Net Asset
| KALV Stock | USD 10.07 0.08 0.79% |
Kalvista Pharmaceuticals fundamentals help investors to digest information that contributes to Kalvista Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kalvista Stock. The fundamental analysis module provides a way to measure Kalvista Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kalvista Pharmaceuticals stock.
Kalvista | Net Asset |
Kalvista Pharmaceuticals Company Net Asset Analysis
Kalvista Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Kalvista Pharmaceuticals Net Asset | 235.4 M |
Most of Kalvista Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kalvista Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kalvista Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Kalvista Pharmaceuticals is extremely important. It helps to project a fair market value of Kalvista Stock properly, considering its historical fundamentals such as Net Asset. Since Kalvista Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kalvista Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kalvista Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Kalvista Total Assets
Total Assets |
|
Based on the recorded statements, Kalvista Pharmaceuticals has a Net Asset of 235.4 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Kalvista Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kalvista Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kalvista Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kalvista Pharmaceuticals by comparing valuation metrics of similar companies.Kalvista Pharmaceuticals is currently under evaluation in net asset category among its peers.
Kalvista Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kalvista Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kalvista Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kalvista Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Kalvista Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kalvista Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kalvista Pharmaceuticals' value.| Shares | Emerald Advisers, Llc | 2024-09-30 | 836 K | Geode Capital Management, Llc | 2024-09-30 | 831 K | State Street Corp | 2024-06-30 | 756.4 K | Dafna Capital Management Llc | 2024-09-30 | 723.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 677.2 K | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 651 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 607 K | Silverarc Capital Management, Llc | 2024-06-30 | 560.9 K | Saturn V Capital Management Llc | 2024-09-30 | 556.5 K | Vr Adviser, Llc | 2024-09-30 | 6.2 M | Tang Capital Management Llc | 2024-09-30 | 4.3 M |
Kalvista Fundamentals
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 331.52 M | ||||
| Shares Outstanding | 49.22 M | ||||
| Shares Owned By Insiders | 1.34 % | ||||
| Shares Owned By Institutions | 98.66 % | ||||
| Number Of Shares Shorted | 6.87 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.89 X | ||||
| Price To Sales | 107.42 X | ||||
| Gross Profit | (80.28 M) | ||||
| EBITDA | (134.28 M) | ||||
| Net Income | (126.64 M) | ||||
| Cash And Equivalents | 142.08 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 7.32 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 17.51 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (89.23 M) | ||||
| Short Ratio | 24.86 X | ||||
| Earnings Per Share | (3.57) X | ||||
| Target Price | 29.17 | ||||
| Number Of Employees | 150 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 499.54 M | ||||
| Total Asset | 235.4 M | ||||
| Retained Earnings | (469.73 M) | ||||
| Working Capital | 202.88 M | ||||
| Current Asset | 54.95 M | ||||
| Current Liabilities | 4.27 M | ||||
| Net Asset | 235.4 M |
About Kalvista Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kalvista Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kalvista Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kalvista Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.